Tag: Pi-Cardia
First US commercial cases performed with ShortCut leaflet modification device
Pi-Cardia has announced the first commercial procedures with its ShortCut dedicated leaflet modi...
ShortCut leaflet splitting device gains US FDA market clearance
The US Food and Drug Administration (FDA) has provided market clearance for the ShortCut (Pi-Car...
EuroPCR 2024: Leaflet splitting device may offer efficient option for avoiding coronary obstruction during valve-in-valve procedures
Insights from the investigational device exemption (IDE) pivotal study of the Shortcut (Pi-Cardia) l...
Pi-Cardia appoints Gary Gratson to lead commercialisation of ShortCut
Pi-Cardia has appointed Gary Gratson to lead commercial operations for ShortCut, its dedicated l...
First US procedure performed using ShortCut leaflet splitting device
Pi-Cardia has announced that the first patient in the USA has been successfully treated with ShortCu...
Pi-Cardia closes a US$27 million financing round led by Sofinnova Partners
Pi-Cardia has closed a US$27 million round of financing, led by Sofinnova Partners. A press rele...
Leaflex Performer: A non-implant based treatment for aortic stenosis
Given sufficient time, all bioprosthetic valves fail—whether they are surgical or transcatheter ...
EuroPCR 2018: First-in-human study of Leaflex Performer for aortic stenosis initiated
Pi-Cardia has recently started its first-in-human study with its Leaflex Performer catheter system. ...
